← Back to Search

Diagnostic Test

PET/MR Imaging for COVID-19

N/A
Recruiting
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must be at least 21 years of age
Be older than 18 years old
Must not have
History of non-MRI compatible surgeries, implants, or activities
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a brain-dedicated PET insert for an MR scanner can be used to study the metabolism and perfusion of Covid-19 negative and positive/once positive subjects.

Who is the study for?
This trial is for adults over 21 who've had a low radiation exposure in the past year and are healthy enough for imaging studies. They must have proof of COVID-19 testing done between 20 to 180 days before the scan but can't join if they're pregnant, nursing, allergic to PET radiotracers, or have non-MRI safe surgeries or implants.
What is being tested?
The study tests a new brain-focused PET insert used inside an MR scanner on people with and without past COVID-19 infection. It aims to create protocols for simultaneous PET/MR images that show both brain function (metabolism/perfusion) and structure.
What are the potential side effects?
Potential side effects may include reactions related to the injected radiotracer such as discomfort at injection site or allergic reactions, although specific side effects are not detailed in this summary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 21 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had surgeries or implants that are not safe for MRI.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
PET/MR

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Covid-19 Positive/Infected PopulationExperimental Treatment1 Intervention
5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
Group II: Covid-19 Negative/Uninfected PopulationExperimental Treatment1 Intervention
5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,471 Previous Clinical Trials
17,501,768 Total Patients Enrolled

Media Library

Injected radiotracer with PET Insert (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT04954248 — N/A
Coronavirus Research Study Groups: Covid-19 Negative/Uninfected Population, Covid-19 Positive/Infected Population
Coronavirus Clinical Trial 2023: Injected radiotracer with PET Insert Highlights & Side Effects. Trial Name: NCT04954248 — N/A
Injected radiotracer with PET Insert (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04954248 — N/A
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top